Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Dose Response Study of Transdermal Human Insulin in Patients

NCT: NCT05159453 · NOT_YET_RECRUITING

NCT IDNCT05159453
StatusNOT_YET_RECRUITING
Start Date2027-09-02
Completion2027-12-15

Brief Summary

A 21-Day open label study of transdermally delivered human insulin in Type 2 Diabetics as measured by response of down modulation of glucose after dosing of Insulin as compared to historic patient response to injected insulins.

Frequently Asked Questions

What is Dose Response Study of Transdermal Human Insulin in Patients?

Dose Response Study of Transdermal Human Insulin in Patients is a clinical trial registered under NCT05159453. Current status: NOT_YET_RECRUITING.

What is the status of NCT05159453?

The current status of NCT05159453 (Dose Response Study of Transdermal Human Insulin in Patients) is: NOT_YET_RECRUITING.

When did Dose Response Study of Transdermal Human Insulin in Patients start?

Dose Response Study of Transdermal Human Insulin in Patients started on 2027-09-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑